Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices.
The signing ceremony followed a working meeting between Mr Li and Mr Hansen, at which the Commissioner introduced China's drug regulation and the development of its pharmaceutical industry. In recent years, the two sides have carried out a series of exchanges in drug evaluation, testing and inspection as well as medical device regulation, Mr Li said, noting that he hopes to push forward exchanges and collaboration between the drug regulatory authorities of the two countries into broader fields and deeper level.
Mr Hansen said Denmark attaches great importance to cooperation with China in drug regulation and is willing to further deepen bilateral cooperation through closer exchange activities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze